CERS Stock Analysis: Buy, Sell, or Hold?
CERS - Cerus Corp
$3.16
0.16 (5.33%)
▲
5d:
+10.49%
30d:
+17.04%
90d:
+68.98%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When CERS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: CERS is 8.2% above its trading range ($2.92). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: CERS is 8.2% above its trading range ($2.92). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: CERS is currently trading at $3.16, which is considered extended relative to its 30-day fair value range of $2.56 to $2.92.
Technical Outlook: Technically, CERS is in a strong uptrend. The price is approaching resistance at $3.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: CERS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.67 (+47.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CERS is in a strong uptrend. The price is approaching resistance at $3.21. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: CERS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $4.67 (+47.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.56 -
$2.92
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+8.2% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.3%)
- BULLISH: Trading 47.7% below Wall St target ($4.67)
- CAUTION: Extended 8.2% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$2.56 -
$2.92
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.52
Resistance Level
$3.21
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Wall Street Target
$4.67
(+47.7%)
Revenue Growth (YoY)
24.1%
Profit Margin
-4.4%
Share & Embed Analysis
Last updated: July 02, 2026 10:48 PM ET
Data refreshes hourly during market hours. Next update: 11:47 PM
Data refreshes hourly during market hours. Next update: 11:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CERS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Kevin Dennis Green
SELL
127544 shares
2026-03-12
Richard J Benjamin
SELL
101740 shares
2026-03-12
Vivek K Jayaraman
SELL
165200 shares
2026-03-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$75 | 65 BUY |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$85 | 58 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$387 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$240 | 65 BUY |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 65 BUY |
